Skip Navigation
The Catalyst

Research Grants

Library Science & Informatics
David Rivers
Corp. Support-National Conference on Health Disparities, $25,000, from multiple sponsors, February 2007 to December 2016

Oral Health Sciences — College of Dental Medicine
Keith Kirkwood
Integrating Biomechanics and Cell Biology to Understand TMJ Pathology, $142,858 from Clemson University (RO1 DE021134/1602-209-2008855), March through February 2015

Biochemistry & Molecular Biology — College of Medicine
Tilman Heise
Screen for Inhibitors of La-Dependent IRES-Mediated Translation in Cancer Cells, $300,906 from NIH/National Cancer Institute (5RO1CA172567-02), May to April 2016

Cell & Molecular Pharmacology —College of Medicine
Krystal Nolan

Role of EZH2 in Extracellular HSP90 Mediated Prostate Cancer Tumorigenesis, $42,676 from NIH/National Cancer Institute (5F31CA177015-02), May to April 2015

Carolyn Britten
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin) in Patients with Solid Tumors, $211,040, from SCRI Development Innovations, LLC (ME-344-002), April 2014 to 2018

Frank Cuoco
reMARQable: nMARQ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation – IDE 120289, $578,473, from Biosense Webster, Inc., May to December 2018

Harry A. Drabkin
A Rollover Protocol to Allow Continued Access to Tivozanib Hydrochloride (AV951) for Subjects Enrolled in Other Tivozanib Hydrochloride Protocols, $1,355, from AVEO Pharmaceuticals (AV-951-09-901), December 2012 to December 2019

Gary Gilkeson
New Target Identification in Lupus, $56,073, from Berg, LLC, December 2013 to October 2018

Charles S. Greenberg
Multicenter, Randomized, Active-Controlled Efficacy and Safety Study Comparing Extended Duration Betrixaban with Standard of Care Enoxaparin for the Prevention of Venous Thromboembolism in Acute Medic, $62,348, from Portola Pharmaceuticals, March 2014 to September 2015

Andrew Kraft
Identification of PIM Kinase Substrates in Sensitive DLBCL, Myeloma and Prostate Cancer Cells by Mass Spectrometry, $60,000, by Astrazeneca, April to April 2015

Medicine —College of Medicine
Alice Mims

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia, $8,370, from INC Research (M13-982), May to July 8, 2014

Jim Oates

  • A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-dose, 24-week study to Evaluate the Efficacy and Safety of Atacicept in Subjects with SLE, $132,388, from Quintiles Pacific, Inc. (EMR700461-023), May to May 2017
  • Identification of Dysregulated Pathways in SLE, $76,025, by Genentech, March to March 2016

Eric Powers
Lipid Rich Plaque Outcomes Study, $651,250, by InfraReDx, Inc., from April to December 2018

Paula Ramos
DNA Methylation Biomarkers of Scleroderma-Associated Interstitial Lung Disease, $74,750, NIH/National Institute of Arthritis and Musculoskeletal Skin Diseases (1RO3ARO65801-01), May to April 2017

Keisuke Shirai

  • A Phase lb Dose Escalation/Randomized Phase II, Multicenter, Open-Label Study of BYL719 in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, $234,960, by Novartis Corp (BYL719X2104), May to May 2016
  • An Open-Label, Multi-center, Expanded Treatment Protocol of Oral LDK378 in Adult Patients with Non-small Cell Lung Cancer characterized by ALK (+) Rearrangements in Patients Previously, $171,800, by Novartis Corp (CLDK378A2402), February to June 2016

Robert K.  Stuart

  • A Phase ½ Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia, $150,956, from Astrellas Pharma US, April to April 2017
  • Phase III, Multi-Center, Randomized Trial of CPS-351 Liposome Injection vs. Cytarabine and Daunorubicin in Patients 60-75 Years of Age, $118,572, Celator Pharmaceuticals (CLTR0310-301), December 2012 to December 2017

Nichole Tanner
A Multi-Center Trial Comparing Standard 22-Gauge and 22-Gauge Procor Needles for Endobronchial Ultrasound, $340,410, from Cook Inc., April to April 2016

Adrian Van Bakel
Effect of Everolimus Immunotherapy on Anti-HLA Antibody Mediated Activation of Endothelial Cells. A Retrospective Mechanistic Substudy of the Novartis Sponsored Trial, $577, from UCLA (1625-P-PC853 RAD Substudy), October 2011 to December

Timothy Whelan
Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_PRO), $208,474, from Duke University, May to March 2019

Microbiology & Immunology — College of Medicine
Chrystal Paulos
Costimulatory Mechanisms of Antitumor Th17 Cell Immunity, $300,907, from NIH/National Cancer Institute (5RO1CA175061-02), from May to April 2018

Mike Schmidt
Management of the Nuclear Advisory Committee, $90,828, from SCUREF (DE-NE0000393/DENE005), March to February 2016

Jessica Thaxton
Chemotherapy Necessitates Increased Immune Control of Chronic HHVs: A Cause of Persistent Inflammation Enabling Protracted Fatigue in Breast Cancer Survivors, $125,748, from the Department of Defense (W81XWH-11-1-0704-P00001), May to April 2015

Chenthamarakshan Vasu
Antigen Specific Suppression of Autoimmunity in Lupus, $100,000, from Lupus Research Institute,  August 2011 to February

July 10, 2014



© 2013  Medical University of South Carolina | Disclaimer